Welcome to our dedicated page for Aditxt SEC filings (Ticker: ADTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aditxt, Inc. (NASDAQ: ADTX) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into how Aditxt describes its business as a social innovation platform accelerating promising health innovations, as well as its governance, capital structure, and key agreements.
Through Forms 10-K and 10-Q, investors can review Aditxt’s periodic financial statements and management discussions, including information about its programs in immune health, precision diagnostics, autoimmunity, cancer and early disease detection, infectious diseases, and women’s health. When Aditxt files a Form 12b-25 (NT 10-Q), it provides an explanation for delayed quarterly reports and indicates the expected timing of the filing.
Current reports on Form 8-K document material events such as the implementation of a 1-for-113 reverse stock split, amendments to the certificate of incorporation, entry into or termination of material definitive agreements, and financing arrangements. For example, Aditxt has used Form 8-K to report the approval and effectuation of its reverse stock split, the termination of its Amended and Restated Merger Agreement with Evofem Biosciences, Inc., and the issuance of notes and other securities.
Proxy statements on Schedule 14A (such as definitive proxy statements for special meetings) detail proposals submitted to stockholders, including approvals for issuances of common stock underlying various series of convertible preferred stock and warrants, the adoption of an Employee Stock Purchase Plan, amendments to the company’s equity incentive plan, authority to effect a reverse stock split, and a non-binding advisory vote on a proposed name change to “bitXbio, Inc.” These documents also describe meeting logistics and voting procedures.
Investors interested in ownership and governance can review information on security ownership of certain beneficial owners and management within proxy materials, while exhibits to Forms 8-K and other reports may include key agreements, amendments, and certificates of amendment. Stock Titan’s interface surfaces these filings as they appear on EDGAR and can pair them with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand complex items such as capital structure changes, equity plans, and material contracts.
For those tracking insider and security-holder activity, related forms and disclosures filed by Aditxt and its insiders can be viewed alongside the company’s core reports. Together, these filings form the primary regulatory record of how Aditxt presents its strategy, risk factors, and significant corporate actions to the market.
Aditxt, Inc. (ADTX) reported very limited revenue and heavy losses in its latest quarter. For the nine months ended September 30, 2025, sales were only $2,770, while the company recorded a net loss of $37,555,792 and used $16,442,686 of cash in operating activities.
Cash on hand was just $163,041, against total liabilities of $20,658,817, resulting in a stockholders’ equity deficit of $8,859,178. Management states there is substantial doubt about Aditxt’s ability to continue as a going concern and notes constraints on raising capital under the Form S-3 “baby shelf” limitation.
A major driver of the loss was a $23,001,919 impairment on its Evofem F-1 Preferred Stock investment, reducing the Evofem-related balance to $7,051,933. The company also faces high-cost debt, lease payment arrears, multiple recent reverse stock splits, and warns that a potential Nasdaq delisting could further hurt liquidity, valuation, and access to financing.
Aditxt, Inc. (ADTX) submitted a Form 12b-25 to notify that its Form 10-Q for the quarter ended September 30, 2025 will be filed late. The company states that the compilation, dissemination and review of the information required for the quarterly report created time constraints that made a timely filing impracticable without undue hardship and expense. Aditxt states that it undertakes the responsibility to file the Form 10-Q no later than 5 days after its original due date under the Rule 12b-25 extension framework.
Aditxt, Inc. (ADTX) approved a 1-for-113 reverse stock split of its issued and outstanding common stock. The split becomes effective at 4:01 p.m. Eastern Time on October 31, 2025, and shares will begin trading on a split-adjusted basis on November 3, 2025. The stated purpose is to bring the company into compliance with Nasdaq’s minimum bid price requirement.
The reverse split does not change the number of authorized shares or the $0.001 par value. Exercise prices and share amounts for outstanding options, restricted stock units, warrants, and plan reserves will be adjusted proportionately, and any fractional shares will be rounded up to the next whole share. The stock will continue trading under the ticker ADTX, and has been assigned a new CUSIP number 007025885.
Aditxt, Inc. reported that Evofem Biosciences terminated the parties’ Amended and Restated Agreement and Plan of Merger, effective immediately. Evofem cited Section 8.1(b)(ii) (the end date having passed) and Section 8.1(b)(iv) (failure to obtain shareholder approval at the October 20, 2025 special meeting) as the bases for termination.
The company stated that no termination fee or other early-termination penalty is payable by Aditxt in connection with a termination under those sections. Certain provisions survive, including the parties’ Non‑Disclosure Agreement dated October 23, 2023. Aditxt is reviewing the notice and evaluating its rights and remedies under the Merger Agreement and applicable law.
Aditxt, Inc. appointed Christopher J. Porcelli as its General Counsel, Chief People Officer and Corporate Secretary, effective September 30, 2025. Under his offer letter, he will receive an annual base salary of $350,000, with employment on an at-will basis and eligibility to participate in employee benefit plans generally available to senior executives. The offer also includes an initial equity award under Aditxt’s equity incentive plan, subject to Compensation Committee approval, which is expected to vest over three years based on continued service. The company plans to file the full offer letter as an exhibit to its next periodic report.
Aditxt, Inc. reporting person Christopher J. Porcelli filed an initial Form 3 disclosing his relationship to the company as General Counsel, CPO & CS. The event date noted is 09/30/2025 and the filing is signed on 10/03/2025. The Form 3 shows 0 shares of Common Stock beneficially owned and lists no derivative securities. No indirect ownership or additional holdings are reported on this form.
Aditxt, Inc. (ADTX) Form 3 filed by Hermina Sylvia reports an initial statement of beneficial ownership for a director. The filing states the report date for the triggering event as 10/23/2024 and indicates the reporting person is a Director of Aditxt. The Form 3 explicitly states: No securities are beneficially owned by the reporting person at the time of filing. The form is signed by Sylvia Hermina on 09/29/2025.
Aditxt, Inc. reconvened its annual stockholder meeting on September 23, 2025 after an earlier adjournment to allow more voting time. A total of 1,665,180 common shares, representing 33.59% of voting power, were present, which was enough to reach a quorum.
Stockholders re-elected Amro Albanna, Shahrokh Shabahang, Brian Brady, Charles Nelson and Sylvia Hermina to serve as directors until the 2026 annual meeting, based on vote totals that all showed more votes "for" than "withheld." They also ratified dbbmckennon LLC as independent auditor for the fiscal year ending December 31, 2025, with 1,506,751 votes for, 92,439 against, and 65,990 abstentions.
Importantly, stockholders approved giving the board discretionary authority to implement a reverse stock split of the common stock at a ratio between 1-for-5 and up to 1-for-250, with the exact ratio and decision whether to proceed to be set by the board within one year. This proposal received 1,178,583 votes for, 473,001 against, and 13,596 abstentions.
Aditxt, Inc. issued senior unsecured notes totaling an aggregate original principal amount of $212,500 for a purchase price of $170,000, producing an original issue discount of $42,500. The Notes pay interest at 10% per annum and mature on September 30, 2025. The Notes include standard events of default.
The company agreed that 100% of gross proceeds from any future at-the-market offering, equity line or similar sales of common stock received on or after the note date must be used to repay the Notes. After the Maturity Date and until the Notes are satisfied, the company is prohibited from taking certain actions, including incurring additional indebtedness, redeeming capital stock, or declaring or paying dividends.
Aditxt, Inc. reported amendments to its merger agreement with Evofem Biosciences and outlined a series of parent equity investments tied to that transaction. The company agreed to purchase incremental shares of Evofem's Series F-1 Preferred Stock in staged investments: $500,000 on or before July 12, 2024, $500,000 on August 9, 2024, a later-scheduled Third investment that was amended several times and ultimately adjusted to $720,000 with an October 2, 2024 target, and a Fourth investment increased to $2.28 million with later deadlines moved into late 2024 and 2025. Multiple amendments also extended the merger End Date to September 30, 2025, and the parties agreed Evofem will use commercially reasonable efforts to hold the Company Shareholders Meeting no later than September 26, 2025. The Company additionally agreed to invest $1,500,000 in Evofem no later than April 7, 2025 in exchange for additional F-1 Preferred Stock and/or, at the Company's option, senior subordinated notes.